Turkish Journal of
Cardiovascular Nursing
Original Article

Factors Associated with Phlebitis in Amiodarone Administration by Changing the Infusion Site*


Department of Nursing, Ordu University, Faculty of Health Sciences, Ordu, Turkey


Department of Nursing, Florence Nightingale Faculty of Nursing, Istanbul University - Cerrahpaşa, Istanbul, Turkey

Turkish Journal of Cardiovascular Nursing 2022; 13: 167-172
DOI: 10.5543/khd.2022.214481
Read: 444 Downloads: 48 Published: 22 December 2022

Objective: This study aimed to determine the incidence of phlebitis in patients undergoing amiodarone treatment by changing the infusion site and affecting factors in the coronary intensive care unit.

Methods: A total of 30 patients who received similar doses of amiodarone treatment for 12 months in the coronary intensive care unit were examined. The catheter, duration, catheter diameter (20-22 G) of amiodarone therapy, etc., factors, and factors related to phlebitis formation were examined. Descriptive statistics were used to analyze the data.

Results: In the study, 60 catheters undergoing amiodarone therapy applied to 30 patients were examined. It was observed that phlebitis developed in 9 (30%) out of 30 patients and 10 (16.6%) out of 60 catheters. More occurrences of phlebitis were detected in cases using a 22-G catheter (P < .05). Phlebitis occurred more commonly in women (37.5%) and catheters were attached to the intra-elbow area (50%). However, the development of phlebitis with these variables was not statistically different (P > .05).

Conclusion: In the present study, phlebitis developed in 30% of the patients. Therefore, it is recommended to change the infusion site after 12 hours of amiodarone infusion, and if possible, to apply with a central venous catheter.

Cite this article as: Kalkan Uğurlu Y, Enç N. Factors associated with phlebitis in amiodarone administration by changing the infusion site. Turk J Cardiovasc Nurs 2022;13(32):167-172.

EISSN 2149-4975